Biofrontera Inc (BFRI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biofrontera Inc (BFRI) has a cash flow conversion efficiency ratio of -0.278x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.66 Million) by net assets ($5.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Biofrontera Inc for the company's overall valuation and market capitalisation.
Biofrontera Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Biofrontera Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Biofrontera Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biofrontera Inc ranked by their cash flow conversion efficiency. Explore BFRI operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
UMS Holdings Bhd
KLSE:7137
|
0.018x |
|
New Zealand Energy Corp
V:NZ
|
-0.179x |
|
PYRAMID AG NA O.N.
XETRA:M3B
|
0.092x |
|
Citigold Corporation Limited
F:CHP
|
-0.005x |
|
Trailblazer Merger Corporation I Class A Common Stock
NASDAQ:TBMC
|
0.038x |
|
Trigyn Technologies Limited
NSE:TRIGYN
|
-0.077x |
|
Inovalis Real Estate Investment Trust
TO:INO-UN
|
-0.028x |
|
Telefast Indonesia
JK:TFAS
|
0.023x |
Annual Cash Flow Conversion Efficiency for Biofrontera Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Biofrontera Inc from 2019 to 2025. View current stock price of Biofrontera Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $10.48 Million | $-13.36 Million | -1.275x | +44.97% |
| 2024-12-31 | $4.43 Million | $-10.27 Million | -2.317x | +55.40% |
| 2023-12-31 | $4.79 Million | $-24.89 Million | -5.194x | -665.62% |
| 2022-12-31 | $23.88 Million | $-16.20 Million | -0.678x | +71.21% |
| 2021-12-31 | $11.34 Million | $-26.71 Million | -2.356x | -11.02% |
| 2020-12-31 | $5.83 Million | $-12.37 Million | -2.122x | -270.00% |
| 2019-12-31 | $-30.18 Million | $-37.68 Million | 1.248x | -- |
About Biofrontera Inc
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquarte… Read more